TRAIL expression enhancer – Japan (Patent No. 5937029)
Patent Details
Country of RegistrationJapan
Patent No.No. 5937029Registration DateMay 20, 2016
The body has an immune function that produces “anti-cancer substances” on its own to suppress the growth of cancer. Some of the “anti-cancer substances” produced may damage not only cancer cells but also normal cells, just like anti-cancer drugs in the treatment.However, “trails” among such substances have little effect on normal cells and selectively lead cancer cells to apoptosis as an inhibitory effect on cancer growth.We tested whether Aureobasidium (black yeast) culture fluid (hereafter referred to as “Aureo culture fluid”) is useful as an agent that enhances this “trail”.As a result, it was confirmed that β-glucan from barley and β-glucan from baker’s yeast hardly enhanced the expression of trails in humans and mice, whereas Aureobasidium culture fluid enhanced the production of trails.
This Japanese patent (Patent No. 5937917) covers Aureobasidium pullulans-derived β-glucan as a TRAIL expression enhancer — TRAIL being a cytokine that selectively induces apoptosis in cancer cells.
AP β-glucan enhances expression of TRAIL (TNF-Related Apoptosis-Inducing Ligand) in immune cells, potentially amplifying selective cancer cell killing. Enhanced TRAIL expression from immune cells (particularly NK cells) could provide a targeted anti-tumor mechanism complementary to AP-glucan's other immunostimulatory effects.
TRAIL expression enhancement represents a direct anti-tumor mechanism for AP-glucan beyond general immune activation. As TRAIL selectively kills cancer cells while sparing normal cells, AP-glucan's TRAIL-enhancing activity could be particularly valuable in cancer prevention and complementary oncology care.
Uchiyama H., Iwai A., Nagahara Y.. TRAIL expression enhancer – Japan (Patent No. 5937029). Japanese Patent Office. 2023.
For scientific reference only. Not medical advice. Consult a qualified healthcare professional. See our Medical Disclaimer.